Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 4/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879466 | 1.00 | HCAR2 (0.33) | HCAR2CTSKCA1CA2CA7 | |
| SCHEMBL7536978 | 0.77 | HCAR2 (0.59) | HCAR2CTSKCA1CA2CA7 | |
| SCHEMBL3514185 | 0.77 | HCAR2 (0.59) | HCAR2CTSKCA1CA2CA7 | |
| SCHEMBL7571840 | 0.77 | HCAR2 (0.59) | HCAR2CTSKCA1CA2CA7 | |
| SCHEMBL7571847 | 0.77 | HCAR2 (0.59) | HCAR2CTSKCA1CA2CA7 | |
| SCHEMBL375029 | 0.77 | HCAR2 (0.45) | HCAR2ELANEPRKCADGAT1 | |
| SCHEMBL43764 | 0.77 | HCAR2 (0.45) | HCAR2ELANEPRKCADGAT1 | |
| SCHEMBL43004 | 0.77 | HCAR2 (0.45) | HCAR2ELANEPRKCADGAT1 | |
| SCHEMBL1880637 | 0.76 | TDP1 (0.36) | HCAR2DGAT1 | |
| SCHEMBL1880635 | 0.76 | TDP1 (0.36) | HCAR2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-1666440-B1 | METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-7939674-B2 | Process for producing an aromatic unsaturated compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7700642-B2 | Process for producing an aromatic unsaturated compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090111999-A1 | PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20080221337-A1 | Process for Producing an Aromatic Unsaturated Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1666440-A1 | METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221337-A1 | Process for Producing an Aromatic Unsaturated Compound | AHR, AR, ARSA | HCAR2 122/4885CTSK 2069/4885CA1 1520/4885 |
| US-20090111999-A1 | PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND | AHR, AR, ARSA | HCAR2 122/4885CTSK 2069/4885CA1 1520/4885 |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | HCAR2 199/4885CTSK 872/4885CA1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.